Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Objective To update evidence‐based recommendations for the treatment of patients with
ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods We …

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …

Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the
past two decades. With advances in the discernment of immunopathogenesis of this …

Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …

Background The JAK pathway is a potential therapeutic target in ankylosing spondylitis. This
study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients …

Axial spondyloarthritis (axSpA) is an inflammatory disease of the axial skeleton associated
with significant pain and disability. Previously, the diagnosis of ankylosing spondylitis …

Although the pathogenic mechanisms underlying axial spondyloarthritis (axSpA) and
psoriatic arthritis (PsA) are not fully elucidated, several lines of evidence suggest that …

Objective To update the evidence on efficacy and safety of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …

The cytokines IL-23 and IL-17 have an important role in the pathogenesis of, and as a
therapeutic target in, both animal models of chronic inflammation and some human chronic …